EPS for Exelixis, Inc. (EXEL) Expected At $0.03, Profile of 2 Analysts Covering Syntel, Inc. (SYNT)

July 21, 2017 - By Darrin Black

Among 11 analysts covering Syntel Inc. (NASDAQ:SYNT), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Syntel Inc. had 24 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of Syntel, Inc. (NASDAQ:SYNT) has “Outperform” rating given on Thursday, August 20 by Robert W. Baird. The firm has “Hold” rating given on Friday, July 15 by Maxim Group. The stock of Syntel, Inc. (NASDAQ:SYNT) has “Buy” rating given on Thursday, September 10 by Suntrust Robinson. Maxim Group upgraded it to “Buy” rating and $58 target in Wednesday, February 3 report. The rating was downgraded by Suntrust Robinson on Monday, October 24 to “Hold”. The firm earned “Neutral” rating on Monday, April 18 by Robert W. Baird. The firm has “Hold” rating by Cowen & Co given on Tuesday, July 18. The firm has “Hold” rating by Cantor Fitzgerald given on Friday, October 16. On Monday, October 24 the stock rating was downgraded by SunTrust to “Hold”. SunTrust initiated the stock with “Buy” rating in Thursday, September 10 report. See Syntel, Inc. (NASDAQ:SYNT) latest ratings:

20/07/2017 Broker: Maxim Group Rating: Hold
20/07/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $16.0000
18/07/2017 Broker: Cowen & Co Rating: Hold New Target: $18.0000 Maintain
17/02/2017 Broker: Needham Rating: Buy Old Target: $27 New Target: $23 Maintain

Analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report $0.03 EPS on August, 2 after the close.They anticipate $0.19 EPS change or 118.75% from last quarter’s $-0.16 EPS. EXEL’s profit would be $8.86 million giving it 227.25 P/E if the $0.03 EPS is correct. After having $0.05 EPS previously, Exelixis, Inc.’s analysts see -40.00% EPS growth. About 865,749 shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 266.48% since July 21, 2016 and is uptrending. It has outperformed by 249.78% the S&P500.

Exelixis, Inc. is a biopharmaceutical company. The company has market cap of $8.05 billion. The Firm is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. It has a 2546.22 P/E ratio. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Investors sentiment decreased to 1.04 in 2016 Q4. Its down 1.03, from 2.07 in 2016Q3. It fall, as 21 investors sold Exelixis, Inc. shares while 78 reduced holdings. 40 funds opened positions while 63 raised stakes. 232.36 million shares or 7.60% more from 215.94 million shares in 2016Q3 were reported. Bancshares Of Ny Mellon Corp holds 0.01% or 1.18M shares in its portfolio. Vanguard Group Incorporated Inc holds 0.02% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL) for 21.04M shares. Nationwide Fund Advsr, Pennsylvania-based fund reported 176,390 shares. Tiaa Cref Management Ltd invested in 1.24M shares or 0.01% of the stock. 1.95M are held by Geode Capital Management Limited Liability Com. United Kingdom-based Oxford Asset Mngmt has invested 0.08% in Exelixis, Inc. (NASDAQ:EXEL). Teacher Retirement Of Texas holds 0% in Exelixis, Inc. (NASDAQ:EXEL) or 18,447 shares. Emerald Advisers Pa holds 0.83% or 1.31M shares in its portfolio. Price T Rowe Incorporated Md reported 0.03% in Exelixis, Inc. (NASDAQ:EXEL). Wolverine Asset Ltd Liability Co stated it has 27,434 shares or 0.01% of all its holdings. Commerzbank Aktiengesellschaft Fi reported 11,337 shares. Cambridge Inv Research Advsrs reported 11,270 shares stake. Endurant Cap Mngmt Limited Partnership accumulated 60,870 shares. Perceptive Advisors Limited has 0.05% invested in Exelixis, Inc. (NASDAQ:EXEL) for 46,361 shares. 422,461 are held by Gotham Asset Mgmt Llc.

Among 8 analysts covering Exelixis (NASDAQ:EXEL), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Exelixis had 16 analyst reports since January 19, 2016 according to SRatingsIntel. Oppenheimer maintained the shares of EXEL in report on Thursday, June 29 with “Hold” rating. The firm has “Hold” rating by Oppenheimer given on Monday, July 10. The firm earned “Hold” rating on Monday, June 5 by Oppenheimer. Oppenheimer maintained Exelixis, Inc. (NASDAQ:EXEL) on Monday, June 19 with “Hold” rating. Deutsche Bank initiated Exelixis, Inc. (NASDAQ:EXEL) rating on Thursday, November 3. Deutsche Bank has “Buy” rating and $17 target. William Blair maintained Exelixis, Inc. (NASDAQ:EXEL) on Wednesday, June 14 with “Buy” rating. SunTrust initiated the stock with “Buy” rating in Thursday, July 13 report. Piper Jaffray upgraded the shares of EXEL in report on Monday, October 10 to “Overweight” rating. The firm earned “Buy” rating on Monday, April 4 by Stifel Nicolaus. Oppenheimer initiated the shares of EXEL in report on Monday, June 12 with “Hold” rating.

Since February 1, 2017, it had 0 insider buys, and 22 sales for $28.28 million activity. FELDBAUM CARL B had sold 10,000 shares worth $217,700 on Monday, March 20. Shares for $213,000 were sold by MARCHESI VINCENT T on Monday, April 3. MORRISSEY MICHAEL also sold $5.76M worth of Exelixis, Inc. (NASDAQ:EXEL) on Wednesday, May 3. 10,000 shares valued at $216,600 were sold by PAPADOPOULOS STELIOS on Monday, March 20. Shares for $57,600 were sold by Haley Patrick J. on Friday, March 3. Another trade for 50,007 shares valued at $1.13M was made by Schwab Gisela on Wednesday, March 15. Senner Christopher J. also sold $250,800 worth of Exelixis, Inc. (NASDAQ:EXEL) shares.

Syntel, Inc. is a global provider of digital transformation, information technology (IT) and knowledge process outsourcing (KPO) services. The company has market cap of $1.76 billion. The Firm operates through five divisions: Banking and Financial Services, Healthcare and Life Sciences, Insurance, Manufacturing, and Retail, Logistics and Telecom. It currently has negative earnings. Syntel provides a range of services to its clients through its IT services, including Managed Services, Digital One and through its KPO services.

Investors sentiment decreased to 0.67 in 2016 Q4. Its down 0.50, from 1.17 in 2016Q3. It is negative, as 61 investors sold Syntel, Inc. shares while 40 reduced holdings. 26 funds opened positions while 42 raised stakes. 28.53 million shares or 2.78% less from 29.34 million shares in 2016Q3 were reported. Eulav Asset reported 22,700 shares stake. Creative Planning owns 1,290 shares. Credit Suisse Ag invested 0% in Syntel, Inc. (NASDAQ:SYNT). The Missouri-based Kennedy Management has invested 0.03% in Syntel, Inc. (NASDAQ:SYNT). Oakworth Capital accumulated 256 shares. State Treasurer State Of Michigan holds 24,200 shares. Bbva Compass Bancshares owns 14,728 shares. Kcg Inc has 0.01% invested in Syntel, Inc. (NASDAQ:SYNT). Pekin Singer Strauss Asset Management Il owns 599,079 shares. Blackrock Advsr Ltd Company owns 16,445 shares. Geode Management owns 383,111 shares for 0% of their portfolio. Menta Cap Ltd Liability Corp has invested 0.07% in Syntel, Inc. (NASDAQ:SYNT). Adams Diversified Equity Fund Inc invested in 50,800 shares or 0.06% of the stock. Ftb Advsr reported 0% stake. Goldman Sachs Gru has invested 0% in Syntel, Inc. (NASDAQ:SYNT).

About 469,290 shares traded or 49.27% up from the average. Syntel, Inc. (NASDAQ:SYNT) has declined 32.64% since July 21, 2016 and is downtrending. It has underperformed by 49.34% the S&P500.